X842 belongs to the P-CAB class that competitively inhibits the H+, K+-ATPase in the parietal cell and thereby controls gastric acid secretion. Animal studies indicate that X842 will deliver effective control of intragastric acidity during 24 hours in the clinical setting.

This should translate to important and meaningful clinical benefits in areas of unmet medical need in acid related disorders.

First clinical study with X842, an innovative promising treatment for severe erosive GERD, is successfully completed. 

The study showed that X842 was safe and well tolerated. Intragastric acidity, the strongly validated biomarker for healing of eGERD, was possible to maintain above pH 4 for 24 hours after a single dose. 

Abstract on the Phase 1 results, UEGW Oct 2018